Prognostic Mutational Signatures of NSCLC Patients treated with chemotherapy, immunotherapy and chemoimmunotherapy

Prognostic Mutational Signatures of NSCLC Patients treated with chemotherapy, immunotherapy and chemoimmunotherapy

Abstract Different types of therapy are currently being used to treat non-small cell lung cancer (NSCLC) depending on the stage of tumor and the presence of potentially druggable mutations. However, few biomarkers are available to guide clinicians in selecting the most effective therapy for all pati...

Full description

Bibliographic Details
Main Authors: Margaret R. Smith, Yuezhu Wang, Ralph D’Agostino, Yin Liu, Jimmy Ruiz, Thomas Lycan, George Oliver, Lance D. Miller, Umit Topaloglu, Jireh Pinkney, Mohammed N. Abdulhaleem, Michael D. Chan, Michael Farris, Jing Su, Kathryn F. Mileham, Fei Xing
Format: Article
Language:English
Published: Nature Portfolio 2023-03-01
Series:npj Precision Oncology
Online Access:https://doi.org/10.1038/s41698-023-00373-0

Internet

https://doi.org/10.1038/s41698-023-00373-0

Similar Items